Long-term survival of an unresectable upper thoracic esophageal squamous cell carcinoma with severe dysphagia following nasogastric tube feeding and camrelizumab-containing therapy: a case report

For upper thoracic esophageal cancer, surgery is difficult, and the clinical effects of chemoradiotherapy, radiotherapy, and chemotherapy are limited. Camrelizumab is a PD-1 (programmed cell death-1) antibody developed by China. There are few studies on camrelizumab in esophageal cancer. Here, a 66-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tingting, Wang, Rong, Liu, Lianke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798108/
https://www.ncbi.nlm.nih.gov/pubmed/35117657
http://dx.doi.org/10.21037/tcr.2020.03.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798108/
https://www.ncbi.nlm.nih.gov/pubmed/35117657
http://dx.doi.org/10.21037/tcr.2020.03.13

Ejemplares similares